Dropodex 0.1% Eye Drops Notification EL(26)A/10: Phosphate Concentration Missing from Product Information

What Has Been Notified and Why

Rayner Pharmaceuticals Limited has reported to the MHRA that specific batches of Dropodex 0.1% w/v Eye Drops, solution do not include the concentration of phosphates within the product information documents. This is classified as a Class 4 Medicines Defect Notification under reference EL(26)A/10.

This is a documentation deficiency rather than a defect in the medicine itself. The Dropodex eye drops contain phosphate as an excipient. Regulatory requirements state that the concentration of phosphates must be disclosed in the product information, as phosphate-containing ophthalmic products can, in rare circumstances, be associated with corneal calcification in patients with severely compromised corneal epithelium. Without this information in the product documentation, prescribers and dispensers cannot make a fully informed decision for patients where phosphate content is clinically relevant.

What a Class 4 Defect Notification Means

The MHRA's Class 4 category is the lowest severity level of medicines recall or defect notification. A Class 4 notification is issued when the defect is unlikely to cause any adverse health consequences to patients. It is typically used for documentation deficiencies, minor labelling errors, or administrative non-conformances where the medicine itself is unaffected.

In this case, the Dropodex eye drops themselves are physically and chemically unaffected. The medicine has not changed. The defect relates solely to missing information in the accompanying product documentation. The risk to individual patients is considered very low, particularly because Dropodex is used in short post-surgical courses where the cumulative phosphate exposure is limited.

However, the regulatory requirement exists for a reason. Ophthalmologists and pharmacists managing patients with significant corneal surface disease deserve access to complete phosphate concentration data so they can make informed prescribing and dispensing decisions. The notification allows healthcare professionals to be aware of this gap in the available documentation until corrected product information is distributed.

Steps for Ophthalmology and Pharmacy Teams

1. Check your stock against the batch numbers specified in the EL(26)A/10 notice to identify whether you hold affected batches.
2. Follow the return instructions from Rayner Pharmaceuticals for affected batches.
3. Be aware of phosphate content when prescribing or dispensing Dropodex to patients with significantly compromised corneal epithelium, pending receipt of corrected product information from Rayner.
4. Source replacement stock from unaffected batches with complete product information, if required.